HPPD and the Risks of Psychedelic Misuse with Ed Prideaux
Similar Posts
Daniel Carcillo On Psychedelics For TBI, Wesana Partnering With MAPS & Mike Tyson Collaboration
During our time at Wonderland Miami, $PSYC CEO, David Flores,…
Psychedelic Business Spotlight – February 25
This week in psychedelic business news: Core One cheapens psilocybin production; Field Trip eyes Oregon; Small Pharma advances DMT.
Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn
In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.
In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.
From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.
Perhaps, psychedelics can treat mental health issues in general.
Perhaps, ketamine can be used to heal.
In the conversation, MDMA to treat addiction was also discussed.
Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.
With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.
From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.
#Psychedelics #Awakn #PsychedelicStocks
Kevin Colley on Career Ending Injury and His Path to Recovery Through Psychedelic-Therapy
Kevin Colley, a former professional hockey player with over a decade of experience, including a stint with the NHL’s New York Islanders, embarked on a profound journey earlier this year. Invited by fellow retired NHL player Riley Cote, Kevin participated in a transformative psychedelic-focused retreat as a patient of WAKE’s clinical program in Jamaica.
CODY SHANDRAW: The MOST Important Factor Before Investing In Psychedelic Companies
In this interview, David Flores sits down with Cody Shandraw,…
Fixing Your Nervous System Dysregulation May Fix Your Anxiety and Depression with John Wood
In this episode, Sacha Hebbert and John Wood dive into a cautionary tale about the darker side of the psychedelic industry, where cults, and snake oil svengalis pray on open seekers all the time.